<SEC-DOCUMENT>0001171843-24-003256.txt : 20240604
<SEC-HEADER>0001171843-24-003256.hdr.sgml : 20240604
<ACCEPTANCE-DATETIME>20240604083007
ACCESSION NUMBER:		0001171843-24-003256
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240604
FILED AS OF DATE:		20240604
DATE AS OF CHANGE:		20240604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XORTX Therapeutics Inc.
		CENTRAL INDEX KEY:			0001729214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40858
		FILM NUMBER:		241016152

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
		BUSINESS PHONE:		403-607-2621

	MAIL ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_060424.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 <br />UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: left;"><strong></strong><strong>For the month of June 2024</strong></p><p style="text-align: left;"><strong>Commission File Number: 001-40858</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>XORTX Therapeutics Inc.</strong></font></p><p style="text-align: center;"><strong>3710 &#8211; 33rd Street NW, Calgary, Alberta, T2L 2M1</strong></p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>&#160;</p><hr style="page-break-after: always;" noshade="noshade" /><p><strong>SIGNATURE</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" colspan="2" width="6%"><strong>XORTX Therapeutics Inc.&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td colspan="2" width="6%">&#160;(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: June 4, 2024</td><td width="6%">&#160;</td><td width="6%">By:&#160;</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%">&#160;&#160;&#160;&#160;<em>/s/ Allen Davidoff&#160;&#160;</em>&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">Name:&#160;</td><td style="text-align: left;" align="center" width="47%">Allen Davidoff</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">Title:&#160;</td><td style="text-align: left;" align="center" width="47%">Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr></table><p><!--On June 4, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br />(c) Exhibit 99.1. Press release dated June 4, 2024--><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><p style="text-align: center;"><font style="font-size: 10pt;">&#160;</font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">News Release dated June 4, 2024</a> </font></td></tr></table>&#160;</p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>XORTX to Present at BIO International Convention 2024</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">CALGARY, June  04, 2024  (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the &#8220;Company&#8221;) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the<strong>&#160;</strong>BIO International Convention 2024, being held June 3<sup>rd</sup> through 6<sup>th</sup>, 2024. Dr. Allen Davidoff, XORTX&#8217;s CEO, will present an overview on the Company, including the Company&#8217;s progress to date and planned future regulatory and clinical activities.</p>  <p align="justify">Dr. Allen Davidoff, CEO of XORTX, stated, &#8220;This will be the second time that XORTX has been invited to present at the BIO International Convention. This presentation and accompanying meetings represent an opportunity to continue outreach to pharmaceutical partners, licensing contacts and industry partners. XORTX looks forward to a busy, productive week with more than 25 scheduled meetings.&#8221;</p>  <p align="justify">The four-day biotechnology and pharmaceutical science conference will be held at the San Diego Convention Center. The presentation by CEO of XORTX, Dr. Allen Davidoff will take place, on Tuesday, June 4<sup>th</sup> at 3:30 pm Theater 1. The presentation will not be available by webcast.</p>  <p align="justify">Pharmaceutical or biotechnology partners can schedule one-on-one meetings with Dr. Allen Davidoff by registering with BIO International and then proceeding through to the <strong>BIO International 2024 1-on-1 meeting platform.</strong></p>  <p><strong>About XORTX Therapeutics Inc.</strong></p>  <p align="justify">XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Respiratory Viral infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients with kidney disease. Additional information on XORTX is available at www.xortx.com.</p>  <p align="justify">For more information, please contact:</p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td class="hugin" style="max-width:40%; width:40%; min-width:40%;">Allen Davidoff, CEO</td><td class="hugin" style="max-width:1%; width:1%; min-width:1%;">&#160;</td><td class="hugin" style="max-width:59%; width:59%; min-width:59%;">Nick Rigopulos, Director of Communications</td></tr><tr><td class="hugin">adavidoff@xortx.com or +1 403 455 7727</td><td class="hugin">&#160;</td><td class="hugin">nick@alpineequityadv.com&#160;or +1 617 901 0785</td></tr><tr><td class="hugin">&#160;</td><td class="hugin">&#160;</td><td class="hugin">&#160;</td></tr><tr><td class="hugin">Kim Golodetz, LHA Investor Relations</td><td class="hugin">&#160;</td><td class="hugin">&#160;</td></tr><tr><td class="hugin">kgolodetz@lhai.com or +1 212 838 3777</td><td class="hugin">&#160;</td><td class="hugin">&#160;</td></tr><tr><td class="hugin">&#160;</td><td class="hugin">&#160;</td><td class="hugin">&#160;</td></tr></table> <p align="justify"><em>Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. </em></p>  <p><strong>Forward Looking Statements</strong></p>  <p align="justify">This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading &#8220;Risk Factors&#8221; in XORTX&#8217;s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on the SEDAR+ website, www.sedarplus.ca.</p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
